RxDoctor Payments Data

Lawrence Ronning, MD

Ophthalmology · North Canton, OHNPI 1609844612

Payments from drug & device makers

$2,055in general payments, 2019–2025

Across 73 payments — averaging $28.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Ivantis, Inc$202
  • Johnson & Johnson Surgical Vision, Inc.$68
  • Ocular Therapeutix, Inc.$66
  • AbbVie$63
  • Shire North American Group Inc$46
  • plus $129 from 6 others

What the payments were for

  • Food & beverage$1,99397%
  • Education$181%
  • Gifts$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,055 in reported general payments places this provider in the 60th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$83,434
Medicare patients
528
Services billed
856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost62$28,271
XiidraLifitegrast21$20,122
LumiganBimatoprost17$7,608
VyzultaLatanoprostene Bunod22$5,479
CombiganBrimonidine Tartrate/Timolol14$4,385
Latanoprost427$4,030
Dorzolamide-TimololDorzolamide/Timolol/Pf37$3,691
Fluorometholone41$2,681
SimbrinzaBrinzolamide/Brimonidine Tart12$2,441
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$2,058
Famciclovir35$1,994
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat110$1,938
Timolol Maleate71$1,591
Prednisolone Acetate43$1,456
Travoprost18$1,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rocklatan$14$28,27162 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$18$25,60043 claims
AbbVieLumigan, Combigan$63$11,99331 claims
AlconSimbrinza$1,481$2,44112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in North Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →